铁螯合在提高生存率中的作用：骨髓增生异常综合征当前治疗的一个重要组成部分。
Role of iron chelation in improving survival: An integral part of current therapy for myelodysplastic syndromes.
作者信息
Taran Sachi Jain, Taran Rakesh
机构信息
Department of Pediatrics, SAIMS, Indore, Madhya Pradesh, India.
Department of Oncology, MGM Medical College, Indore, Madhya Pradesh, India.
出版信息
South Asian J Cancer. 2015 Oct-Dec;4(4):186-8. doi: 10.4103/2278-330X.175958.
Abstract
This review article highlights the current role of iron chelation in MDS to optimize survival and quality of life. Its role in specific subtypes of MDS is also discussed.
摘要
这篇综述文章强调了铁螯合在骨髓增生异常综合征（MDS）中对优化生存和生活质量的当前作用。文中还讨论了其在MDS特定亚型中的作用。
相似文献
1
Role of iron chelation in improving survival: An integral part of current therapy for myelodysplastic syndromes.
South Asian J Cancer. 2015 Oct-Dec;4(4):186-8. doi: 10.4103/2278-330X.175958.
2
Iron overload and chelation therapy in myelodysplastic syndromes.
Crit Rev Oncol Hematol. 2014 Jul;91(1):64-73. doi: 10.1016/j.critrevonc.2014.01.006. Epub 2014 Jan 24.
3
Diagnosis, management and response criteria of iron overload in myelodysplastic syndromes (MDS): updated recommendations of the Austrian MDS platform.
Expert Rev Hematol. 2018 Feb;11(2):109-116. doi: 10.1080/17474086.2018.1420473. Epub 2018 Jan 2.
4
Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy.
Expert Rev Hematol. 2018 Jul;11(7):577-586. doi: 10.1080/17474086.2018.1486188. Epub 2018 Jun 19.
5
Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes.
Expert Rev Anticancer Ther. 2014 Jul;14(7):817-29. doi: 10.1586/14737140.2014.896208. Epub 2014 Mar 18.
6
The role of iron chelation therapy for patients with myelodysplastic syndromes.
J Natl Compr Canc Netw. 2011 Jan;9(1):65-75. doi: 10.6004/jnccn.2011.0007.
7
Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.
Leuk Res. 2007 Dec;31 Suppl 3:S10-5. doi: 10.1016/S0145-2126(07)70461-7.
8
Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes.
Ann Hematol. 2019 Feb;98(2):339-350. doi: 10.1007/s00277-018-3539-7. Epub 2018 Nov 9.
9
Iron chelation therapy in myelodysplastic syndromes.
Am J Health Syst Pharm. 2010 Apr;67(7 Suppl 2):S10-4; quiz S16. doi: 10.2146/ajhp090654.
10
Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications.
Ann Hematol. 2015 May;94(5):779-87. doi: 10.1007/s00277-014-2274-y. Epub 2014 Dec 18.
引用本文的文献
1
Iron Overload in Myelodysplastic Syndromes: Pathophysiology, Consequences, Diagnosis, and Treatment.
J Adv Pract Oncol. 2018 May-Jun;9(4):392-405. Epub 2018 May 1.
本文引用的文献
1
Iron overload and chelation therapy in myelodysplastic syndromes.
Crit Rev Oncol Hematol. 2014 Jul;91(1):64-73. doi: 10.1016/j.critrevonc.2014.01.006. Epub 2014 Jan 24.
2
Myelodysplastic syndromes: toward a risk-adapted treatment approach.
Expert Rev Hematol. 2013 Oct;6(5):611-24. doi: 10.1586/17474086.2013.840997. Epub 2013 Oct 4.
3
Iron chelation therapy in myelodysplastic syndromes: where do we stand?
Expert Rev Hematol. 2013 Aug;6(4):397-410. doi: 10.1586/17474086.2013.814456.
4
Current therapy of myelodysplastic syndromes.
Blood Rev. 2013 Sep;27(5):243-59. doi: 10.1016/j.blre.2013.07.003. Epub 2013 Jul 27.
5
Efficacy and safety of deferasirox in myelodysplastic syndromes.
Ann Hematol. 2013 Jul;92(7):863-70. doi: 10.1007/s00277-013-1703-7. Epub 2013 Feb 17.
6
Improved survival with iron chelation therapy for red blood cell transfusion dependent lower IPSS risk MDS may be more significant in patients with a non-RARS diagnosis.
Leuk Res. 2012 Nov;36(11):1380-6. doi: 10.1016/j.leukres.2012.08.001. Epub 2012 Aug 24.
7
Pre-transplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT.
Bone Marrow Transplant. 2013 Jan;48(1):146-7. doi: 10.1038/bmt.2012.94. Epub 2012 May 21.
8
Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population.
Ann Hematol. 2012 Sep;91(9):1345-9. doi: 10.1007/s00277-012-1481-7. Epub 2012 May 9.
9
Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS registry.
Leuk Res. 2012 Aug;36(8):1067-70. doi: 10.1016/j.leukres.2012.04.006. Epub 2012 May 6.
10
Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes.
Haematologica. 2012 Sep;97(9):1364-71. doi: 10.3324/haematol.2011.048546. Epub 2012 Mar 14.
Zotero 插件